Committee
Consult the user guide
For assistance, please contact us
Consult the user guide
For assistance, please contact us
Add search criteria
Results: 1 - 1 of 1
Stephen Scott
View Stephen Scott Profile
Stephen Scott
2021-05-17 15:56
Yes, Mr. Chair. Good afternoon.
My name is Stephen Scott, and I work as the director general of policy, strategy and performance here at the National Research Council. I am joined by my colleague, Christine Jodoin, director general of the biologics manufacturing centre project.
The NRC legislative amendments are about positioning the NRC to deliver domestic vaccine manufacturing capacity in Canada going forward. There are two proposed amendments to the National Research Council Act. First, there is a proposed amendment to enable the National Research Council to manufacture and produce medical products, such as vaccines, on a larger scale to respond to pandemics and other public health needs.
Currently, the NRC is authorized to produce medical products, on a smaller scale, for things like clinical trials and experiments. This new authority would provide the NRC with the ability to manufacture vaccines on a larger scale, once the new biologics manufacturing centre at the Royalmount campus in Montreal receives regulatory approval by Health Canada.
Second, there is a proposed amendment to provide the NRC with the ability to incorporate and stand up arm's-length entities, such as not-for-profit organizations. Under this amendment, the NRC would be able to establish special purpose collaboration models that would increase and deepen linkages among NRC researchers, academics and the private sector.
The new biomanufacturing facility, which will be operated through a public-private partnership over the longer term, is an example of where a new collaboration model could be used.
Thank you, and we would be happy to take any questions.
Result: 1 - 1 of 1

Export As: XML CSV RSS

For more data options, please see Open Data